Senoo, Satoru
Ninomiya, Kiichiro
Hotta, Katsuyuki
Kiura, Katsuyuki
Funding for this research was provided by:
AstraZeneca (honoraria, research funding)
MSD K.K. (honoraria)
Bristol-Myers Squibb (honoraria, research funding)
Ono pharmaceutical (honoraria)
Chugai Pharmaceutical (research funding)
Eli Lilly Japan (research funding, honoraria)
Astellas Pharma (research funding)
Article History
Received: 22 November 2018
Accepted: 1 March 2019
First Online: 7 March 2019
Compliance with ethical standards
:
: Satoru Senoo has no conflicts of interest. Kiichiro Ninomiya received honoraria from Astrazeneca, MSD, Bristol-Myers Squibb, and Ono pharmaceutical. Katsuyuki Hotta received honoraria from Astrazeneca, and MSD, and research funding from Chugai pharmaceutical, Eli Lilly Japan, Bristol-Myers Squibb, and Astellas Pharma. Katsuyuki Kiura received honoraria from Astrazeneca, and Eli Lilly Japan, and research funding from Astrazeneca, and Chugai pharmaceutical.